Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Harvard Business School
Medtronic
Dow
Merck

Last Updated: November 28, 2022

CLINICAL TRIALS PROFILE FOR GLEEVEC


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Gleevec

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00015834 ↗ STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia Completed National Cancer Institute (NCI) Phase 1/Phase 2 2001-05-01 Phase I/II trial to study the effectiveness of combining STI571 and chemotherapy in treating patients who have chronic myelogenous leukemia. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. STI571 may stop the growth of leukemia cells. Combining chemotherapy and STI571 may kill more cancer cells
NCT00022737 ↗ Combination Chemotherapy With or Without Peripheral Stem Cell Transplant in Treating Children With Acute Lymphoblastic Leukemia Completed National Cancer Institute (NCI) Phase 3 2002-10-01 This phase II trial is studying how well combination chemotherapy with or without donor peripheral stem cell transplant works in treating children with acute lymphoblastic leukemia. Giving combination chemotherapy before a donor peripheral stem cell transplant helps stop the growth of cancer cells. It also helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets.
NCT00025246 ↗ Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery Completed National Cancer Institute (NCI) Phase 2 2001-09-01 This phase II trial is studying how well imatinib mesylate works in treating patients with gastrointestinal stromal tumor that was completely removed during surgery. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth
NCT00025415 ↗ Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction Completed National Cancer Institute (NCI) Phase 1 2001-08-01 Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase I trial to study the effectiveness of imatinib mesylate in treating patients who have advanced cancer and liver dysfunction
NCT00026169 ↗ Imatinib Mesylate in Treating Patients With Advanced Cancer and Kidney Failure Completed National Cancer Institute (NCI) Phase 1 2001-09-01 Phase I trial to determine the dose of imatinib mesylate that is most effective with the least amount of toxic side effects in treating patients who have advanced cancer and kidney failure. Imatinib mesylate may stop the growth of cancer cells by stopping the enzyme necessary for cancer cell growth. Kidney failure may delay the elimination of imatinib mesylate from the body, which may lead to longer drug exposure and increase toxic side effects
NCT00027586 ↗ Imatinib Mesylate in Treating Patients With Metastatic Melanoma Completed National Cancer Institute (NCI) Phase 2 2001-09-01 RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic melanoma.
NCT00027586 ↗ Imatinib Mesylate in Treating Patients With Metastatic Melanoma Completed M.D. Anderson Cancer Center Phase 2 2001-09-01 RATIONALE: Imatinib mesylate may interfere with the growth of tumor cells and may be an effective treatment for metastatic melanoma. PURPOSE: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have metastatic melanoma.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Gleevec

Condition Name

Condition Name for Gleevec
Intervention Trials
Leukemia 30
Chronic Myelogenous Leukemia 14
Chronic Myeloid Leukemia 14
Chronic Myelogenous Leukemia, BCR-ABL1 Positive 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Gleevec
Intervention Trials
Leukemia 97
Leukemia, Myeloid 78
Leukemia, Myelogenous, Chronic, BCR-ABL Positive 77
Leukemia, Myeloid, Chronic-Phase 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Gleevec

Trials by Country

Trials by Country for Gleevec
Location Trials
United States 671
Canada 54
China 39
Australia 37
United Kingdom 26
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Gleevec
Location Trials
Texas 68
California 47
New York 39
Pennsylvania 34
Illinois 29
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Gleevec

Clinical Trial Phase

Clinical Trial Phase for Gleevec
Clinical Trial Phase Trials
Phase 4 3
Phase 3 18
Phase 2/Phase 3 2
[disabled in preview] 206
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Gleevec
Clinical Trial Phase Trials
Completed 159
Terminated 39
Recruiting 12
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Gleevec

Sponsor Name

Sponsor Name for Gleevec
Sponsor Trials
National Cancer Institute (NCI) 77
Novartis 34
M.D. Anderson Cancer Center 34
[disabled in preview] 51
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Gleevec
Sponsor Trials
Other 210
Industry 127
NIH 82
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
Dow
AstraZeneca
Merck
Boehringer Ingelheim
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.